ArticleJournal of translational medicine2026
The oral microbiome is associated with the diagnosis, prognosis and radiotherapy sensitivity of esophageal cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEsophageal cancer (EC) is a leading cause of cancer-related mortality worldwide and early detection strategies and precise postoperative interventions must be developed. However, the identification of noninvasive biomarkers for the diagnosis and prognosis remains limited.
methodsWe performed 16S rRNA gene sequencing on tongue-coating samples from 440 participants, including 157 EC patients, 167 healthy controls (HCs) and 120 EC patients who received radiotherapy. We characterized the oral microbiome and constructed microbial diagnostic and prognostic classifiers. Furthermore, the oral microbiome of EC who received radiotherapy (n = 120) was characterized.
resultsThe oral microbial diversity of EC patients was increased, with differences in the microbial community between EC patients and HCs. In EC, the genera Veillonella, Streptococcus and Actinomyces were enriched, whereas Porphyromonas and Rothia were depleted. The classifier based on six optimal microbial markers was constructed using random forest algorithm and achieved area under the curves (AUCs) of 93.69% and 95.18% in discovery and validation groups, respectively. After radiotherapy, the oral microbial diversity and richness were significantly reduced. The prevalence of opportunistic pathogens, including Fusobacterium and Porphyromonas, decreased, whereas the prevalence of Streptococcus and Actinomyces increased in EC patients after radiotherapy. Through six months of follow-up, patients were categorized into a progression group (PG) (n = 26) and a nonprogression group (NPG) (n = 106) based on the presence of tumor recurrence, metastasis, and death. A prognostic model based on 13 selected amplicon sequence variants (ASVs) of the oral microbiome was constructed, with an AUC of 99.29%. The random forest analysis identified six key differential ASVs between the PG and the NPG, including Fusobacterium and Gemella. Additionally, twenty-five ASVs associated with nine clinical indicators were identified.
conclusionsOur study provides a comprehensive characterization of the oral microbiome in both EC patients and EC patients after radiotherapy, highlighting the potential of the oral microbiome as noninvasive biomarkers for determining the diagnosis and prognosis of EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.